switching from ozempic to semaglutide Tirzepatide Switching from a compounded to

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Ozempic in the UK based on extensive clinical trial data demonstrating its efficacy and safety profile

Initial Consultation : We conduct a comprehensive health evaluation, including lab testing, body composition analysis, and a full review of your medical history

Results We selected 210 adult patients with a median age of 71 years

Patients can come into the office or do everything from home with a virtual appointment and home delivery

What Clinical Trials Show In large obesity trials: Average weight loss is ~15% of starting body weight with semaglutide 2.4 mg Average weight loss is ~2022% of starting body weight with tirzepatide 15 mg The majority of weight loss occurs within the first year of treatment Plateaus are common after significant weight reduction Some people lose more, some less but a flattening of the weight-loss curve is expected , especially after meaningful progress has already occurred